Scholars Central

Conference abstractPublished 24 Jun 2014

From the research to the clinical practice: The micro-grafts challenge

Authors: A Graziano R D’aquino

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

I n the last twenty years the stem cell research found several problems in transferring the scientific models into clinical practice. The main reason is that the technical approach to the tissue engineering in animal research is not routinely repeatable in medicine, due to legal, clinical and technical issues. The only way to use the regenerative potentials of the tissue up to now in clinical medicine was in the grafting procedures, moving matrix, cells and factors from a healthy niche to an injured niche. The autologous grafts are preferable although they have some limits for the donor site in terms of tissue sacrifice and morbidity. In addition, although the innovations occurred during the last years, a crucial issue for the autografts remains the cell and tissue viability: after collection, it dramatically decreases, to percentages lower than 50% reducing the autograft regenerative capacities. The cells death is due to the vessel interruption and the subsequent reduction of the feeding for the tissue, but reducing the dimensions of the grafts, cutting the tissues to small particles or chips to allow the feeding by fluid diffusion for the first phase of healing, is itself a killer factor and cell death problem remains. RIGENERA protocol is a new approach to the clinical regeneration of the human tissues through autologous micro-graft obtained by a CE Class I innovative medical devices called Rigeneracons. Using the RIGENERA protocol the patient is, at the same time, the donor and the acceptor of calibrated micro-grafts of 50 micron and this system permits to increase the cell viability in the surgical site that need to be regenerated. The dimension of 50 micron has been chosen according the evidence showed from different scientific proofs that in every solid tissue exists a side population rich of progenitor cells characterized by definite dimensions. The goal of Rigenera is to help the collection of viable progenitor after a specific filtration in a sterile suspension that at the end of the process is ready to use as itself or after a mixing with a biomaterial to perform a graft of a biocomplex

Subjects

Biology

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Similar by topic

More from this journal

The newest in Journal of Cell Science & Therapy.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Cell Science & Therapy
  • SubjectBiology
  • BylineArticles whose byline prints “A Graziano R D’aquino”

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels